Navigation Links
MGH Neurological Clinical Research Institute and Prize4Life receive Bio-IT World award
Date:4/12/2013

The Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis (ALS), received a Best Practices Award at the 2013 Bio-IT World Conference & Expo. Presented on April 10, the award acknowledged the creation of the Pooled Resource Open-access ALS Clinical Trials (PRO-ACT) platform.

The PRO-ACT platform was chosen from 33 detailed submissions for the Bio IT World award and was honored in the "Clinical & Health IT" category. The dynamic database helps to accelerate discovery, development and delivery of future ALS treatments by housing the largest dataset from completed Phase II and III clinical trials in ALS. The platform enables the merging of data from global clinical trials, generating a valuable resource for the design of future trials and the identification of novel correlations and disease biomarkers.

The PRO-ACT database, contains more than 8,500 fully deidentified, unique clinical patient records both treatment and placebo data from 17 late-stage industry and academic trials and over 8 million data points, including 1.7 million records of lab test results of ALS patients. "The results garnered through the use of the PRO-ACT platform will benefit more than just the scientific and medical research fields; they will also impact ALS patients and their families, potentially by giving them answers to their currently unanswerable questions," states Alexander Sherman, NCRI director of Systems and a pioneering force behind the launch. "It is an unprecedented opportunity to increase the field's understanding of the ALS patient population and the natural history of the disease."

Melanie Leitner, PhD, Prize4Life chief scientific officer says, "We have been thrilled at the ALS community's enthusiastic response to PRO-ACT since its December 2012 launch, including 117 requests to access the PRO-ACT data from industry, clinicians, biostatisticians and other quantitative experts. It is our belief that open access to this rich treasure of data will attract new ideas and shed new light on this disease. We thank Bio-IT World for the opportunity provided by this award to bring PRO-ACT to the attention of the larger Bio-IT community."

NCRI and Prize4Life created the PRO-ACT database with funding from the ALS Therapy Alliance (http://alstherapyalliance.org) in partnership with the Northeast ALS Consortium (http://www.alsconsortium.org/). Academic institutions and pharmaceutical companies including Sanofi, Novartis, Teva Pharmaceutical Industries and Regeneron Pharmaceuticals contributed data to this initiative, and other potential data donations are currently being pursued. Utilizing the datasets should further encourage collaboration between academic and industry researchers, statisticians and clinicians throughout the world.

"The unique collaborative approach used to create PRO-ACT speaks to the advantages of for-profit, nonprofit and academic centers working together," says Merit Cudkowicz, MD, director of the NCRI and chief of Neurology at MGH. "The PRO-ACT initiative has the power to greatly enhance the design of clinical trials testing new approaches to fight ALS and other challenging neurodegenerative diseases."

The capabilities of the database were put to the test last fall during the DREAM-Phil Bowen ALS Prediction Prize4Life Challenge (http://www.prize4life.org/page/news/10194), in which solvers used a subset of the PRO-ACT dataset to develop algorithms to predict the progress of ALS. The outcome revealed PRO-ACT's benefits increased likelihood of successful trials by providing a tool to measure interpatient variability and the potential to reduce the number of patients needed in a trial by 23 percent.

The Bio-IT World's Best Practices Awards program was established in 2003 to highlight organizations for their outstanding innovations and excellence in the use of technologies and novel business strategies that will advance biomedical and translational research, drug development, and/or clinical trials.


'/>"/>

Contact: Devon Punch
dpunch@partners.org
617-724-7210
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Ivy Neurological Sciences Internship program funded at TGen
2. Kids With Neurological Conditions at Higher Risk of Flu Death: CDC
3. New national clinical trials network for neurological disorders to foster cutting-edge treatments
4. The hidden disorder: Unique treatment proposed for childrens neurological disorder
5. Cedars-Sinai physician-scientist awarded $3M to study most common inherited neurological disorder
6. University Hospitals Neurological Institute to present 6th International 2013 Epilepsy Colloquium
7. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
8. Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough
9. Neurological Wellness Center Posts 700% Sales Increase in 2012; Enters Strategic Alliance with Enbrel Buyer's Club to Provide Low Cost Enbrel
10. NIH clinical trial begins for treatment of rare, fatal neurological disorder
11. New technology may help doctors monitor concussions, aging, and neurological function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... Monica, CA (PRWEB) , ... March 28, 2017 ... ... Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the ... gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already ...
(Date:3/28/2017)... ... 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ages, ... to offer to the discussion of dealing with excess skin oil. “Oily skin is a ... remedies that can help remove the oily shine while keeping the skin fresh and clean,” ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... New patients ... Braasch for leading sleep apnea treatment, with or without a referral. Sleep apnea is ... which can include daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CAMBRIDGE, Mass. , March 28, 2017  Akcea Therapeutics, ... three additions to the company,s board of directors: ... Bessemer Venture Partners. Mr. Gabrieli will serve as chairman of ... Hochberg , former chief commercial officer of Forest Laboratories. ... of Global Biolink Partners. "We are ...
(Date:3/28/2017)... ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ ... dedicated to innovative therapeutics addressing cancer and other ... at the American Association for Cancer Research annual ... April 3 is entitled "Evaluation of ENMD-2076 ... and the second poster to be presented ...
(Date:3/28/2017)... , March 28, 2017 The ... to reach a value of USD 4.5 billion by ... Research, Inc. Proper closure of injured tissues post operation ... function. Postoperative leakages occur in 3% to 15% of ... are responsible for one third of postoperative deaths in ...
Breaking Medicine Technology: